Key Insights
The Monkeypox vaccine and treatment market is experiencing robust growth, driven by increasing incidence rates of monkeypox globally and heightened public health awareness. The market, currently valued at approximately $XX million in 2025 (assuming a logical estimation based on the provided CAGR of 10.1% and a study period from 2019-2033), is projected to reach significant scale by 2033. Key drivers include government initiatives to enhance preparedness and response capabilities for infectious diseases, rising research and development investments focused on developing novel vaccines and therapies, and increasing demand from hospitals and specialty clinics. Market segmentation reveals a substantial share for injectable vaccines due to their efficacy and established distribution channels. The North American market, particularly the United States, holds a dominant position due to higher healthcare expenditure and advanced healthcare infrastructure. However, the market faces certain restraints, including the inherent challenges associated with vaccine development and distribution, particularly in resource-limited settings, as well as potential regulatory hurdles and safety concerns. The competitive landscape is relatively concentrated, with major players like Chimerix, Tonix Pharmaceuticals, Bavarian Nordic, and SIGA Technologies actively shaping the market through product development and strategic partnerships. Future growth will likely be influenced by ongoing research into improved vaccine formulations, expansion into emerging markets, and collaborations between public and private entities to address global health security.
The forecast period (2025-2033) anticipates continued market expansion fueled by sustained public health concerns and ongoing advancements in vaccine technology. Growth in the Asia-Pacific region is projected to be particularly notable, driven by increasing population density, improving healthcare infrastructure in several countries, and rising healthcare expenditure. While challenges remain concerning equitable access to vaccines and treatments, the market is expected to exhibit a sustained CAGR of approximately 10.1% throughout the forecast period, leading to substantial market growth and diversification across various segments and geographical regions. Continued monitoring of disease outbreaks, coupled with effective public health strategies, will significantly impact the trajectory of the monkeypox vaccine and treatment market in the coming years.

Monkeypox Vaccine and Treatment Market: A Comprehensive Report (2019-2033)
This comprehensive report provides an in-depth analysis of the Monkeypox Vaccine and Treatment Market, offering actionable insights for industry stakeholders. Covering the period from 2019 to 2033, with a base year of 2025 and a forecast period of 2025-2033, this report meticulously examines market dynamics, key players, and emerging trends. The market is segmented by product (Vaccine, Other Products: Drugs, Other Drugs: Vaccinia Immune Globulin (VIG)), route of administration (Oral, Injectable), and end-user (Hospitals, Specialty Clinics, Other End-Users). This analysis includes significant industry developments and forecasts the market to reach xx Million by 2033. Key players like Bavarian Nordic A/S, SIGA Technologies, Chimerix Inc, and Tonix Pharmaceuticals Holding Corp are profiled, highlighting their strategic initiatives and market positions.
Monkeypox Vaccine and Treatment Market Market Concentration & Dynamics
The Monkeypox Vaccine and Treatment Market exhibits a moderately concentrated landscape, with a few key players holding significant market share. However, the market is witnessing increasing participation from smaller companies focused on niche segments. Innovation is driven by ongoing research into improved vaccine efficacy and the development of novel antiviral treatments. Regulatory frameworks, varying across different geographies, play a crucial role in market access and product approvals. Substitute products, primarily existing smallpox vaccines, pose a competitive challenge. End-user trends reflect a growing focus on preventative measures and enhanced healthcare infrastructure preparedness. M&A activities are moderately frequent, reflecting consolidation and strategic expansions within the market.
- Market Share: Bavarian Nordic A/S holds a dominant market share, followed by SIGA Technologies and other players. Precise figures are available in the full report.
- M&A Deal Counts: An average of xx deals per year have been observed over the historical period, suggesting moderate levels of consolidation.
- Innovation Ecosystem: Collaborative partnerships between pharmaceutical companies and research institutions are driving innovation.
Monkeypox Vaccine and Treatment Market Industry Insights & Trends
The global Monkeypox Vaccine and Treatment Market is experiencing substantial growth, driven by increasing awareness of monkeypox outbreaks and the need for effective prevention and treatment strategies. Technological advancements in vaccine development and antiviral therapies are contributing significantly to market expansion. The market size was valued at xx Million in 2024 and is projected to reach xx Million by 2033, exhibiting a CAGR of xx% during the forecast period. Evolving consumer behaviors, characterized by increased demand for readily available and effective treatments, are fuelling market growth. The rising incidence of monkeypox cases globally is a key factor propelling the market expansion. Government initiatives and funding towards disease prevention and control also contribute to the market growth.

Key Markets & Segments Leading Monkeypox Vaccine and Treatment Market
The North American region currently dominates the Monkeypox Vaccine and Treatment Market, driven by robust healthcare infrastructure, high healthcare expenditure, and the presence of key market players. Europe is another significant market, with growing demand driven by increased public health concerns and government investments.
- By Product: The Vaccine segment holds the largest market share, owing to its preventative role.
- By Route of Administration: Injectable vaccines currently dominate, but the development of oral treatments holds promising potential for future growth.
- By End-user: Hospitals and specialty clinics are the primary end-users due to their capacity for specialized treatment.
- Drivers:
- Robust healthcare infrastructure in developed nations.
- Increasing government funding for public health initiatives.
- Rising awareness about monkeypox and related health risks.
Monkeypox Vaccine and Treatment Market Product Developments
Recent advancements in vaccine technology include the development of improved formulations with enhanced efficacy and safety profiles. The focus is on optimizing delivery methods and exploring new antiviral drugs targeting the monkeypox virus. These advancements offer enhanced therapeutic options and potentially improved patient outcomes. Companies are investing in innovative manufacturing processes to increase production capacity and ensure vaccine availability.
Challenges in the Monkeypox Vaccine and Treatment Market Market
The market faces challenges including regulatory hurdles in gaining product approvals, potential supply chain disruptions affecting vaccine and drug availability, and intense competitive pressures from established players and new entrants. These factors can impact market growth and access to treatment. Furthermore, the emergence of drug-resistant strains could pose a substantial challenge.
Forces Driving Monkeypox Vaccine and Treatment Market Growth
Key growth drivers include rising monkeypox cases globally, increasing government funding for research and development, technological advancements leading to improved vaccines and treatments, and a growing awareness of the disease among the general population and healthcare professionals. Stringent regulations are also promoting market growth by ensuring the safety and efficacy of products.
Long-Term Growth Catalysts in Monkeypox Vaccine and Treatment Market
Long-term growth will be fueled by ongoing research and development into more effective vaccines and treatments, strategic partnerships between pharmaceutical companies and research institutions, and potential expansion into new geographic markets. Development of novel therapeutic modalities for monkeypox treatment will also enhance market growth.
Emerging Opportunities in Monkeypox Vaccine and Treatment Market
Emerging opportunities include the development of next-generation vaccines with improved efficacy and safety, exploration of novel therapeutic targets, and expansion into emerging markets with limited access to current treatment options. Personalized medicine approaches may also present significant growth opportunities in the future.
Leading Players in the Monkeypox Vaccine and Treatment Market Sector
- Chimerix Inc
- Tonix Pharmaceuticals Holding Corp
- Bavarian Nordic A/S
- SIGA Technologies
Key Milestones in Monkeypox Vaccine and Treatment Market Industry
- September 2022: Bavarian Nordic A/S collaborated with HERA to supply an additional 170,000 doses of MVA-BN smallpox and monkeypox vaccine to EU Member States, Norway, and Iceland. This doubled HERA's vaccine supply for the year.
- September 2022: Bavarian Nordic A/S revised its contract with PHAC to supply IMVAMUNE smallpox vaccine, valued at approximately USD 234 million, plus USD 180 million in contract options.
- August 2022: Bavarian Nordic A/S partnered with the U.S. HHS and GRAM to establish a JYNNEOS vaccine fill and finish line in the U.S.
Strategic Outlook for Monkeypox Vaccine and Treatment Market Market
The Monkeypox Vaccine and Treatment Market presents significant growth potential driven by ongoing research, increased public health awareness, and the need for effective prevention and treatment strategies. Strategic opportunities exist for companies to focus on developing innovative products, establishing strong partnerships, and expanding into underserved markets. The market is poised for continued expansion, driven by both preventative and curative treatment options.
Monkeypox Vaccine and Treatment Market Segmentation
-
1. Product
-
1.1. Vaccine
- 1.1.1. JYNNEOS/Imvanex
- 1.1.2. Smallpox Vaccine
- 1.1.3. Other Products
-
1.2. Drugs
- 1.2.1. Tecovirimat
- 1.2.2. Brincidofovir
- 1.2.3. Other Drugs
- 1.3. Vaccinia Immune Globulin (VIG)
-
1.1. Vaccine
-
2. Route of Administration
- 2.1. Oral
- 2.2. Injectable
-
3. End-user
- 3.1. Hospitals
- 3.2. Specialty Clinics
- 3.3. Other End-Users
Monkeypox Vaccine and Treatment Market Segmentation By Geography
- 1. North America
- 2. Europe
- 3. Asia Pacific
- 4. Middle East and Africa
- 5. South America

Monkeypox Vaccine and Treatment Market REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 10.10% from 2019-2033 |
Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increase in Prevalence of Monkeypox Infection; Government Initiatives to Combat Outbreak of Monkeypox
- 3.3. Market Restrains
- 3.3.1. Side Effects Associated with the Vaccine and Treatment
- 3.4. Market Trends
- 3.4.1. JYNNEOS/Imvanex by Vaccine Segment is Expected to Witness Growth Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Vaccine
- 5.1.1.1. JYNNEOS/Imvanex
- 5.1.1.2. Smallpox Vaccine
- 5.1.1.3. Other Products
- 5.1.2. Drugs
- 5.1.2.1. Tecovirimat
- 5.1.2.2. Brincidofovir
- 5.1.2.3. Other Drugs
- 5.1.3. Vaccinia Immune Globulin (VIG)
- 5.1.1. Vaccine
- 5.2. Market Analysis, Insights and Forecast - by Route of Administration
- 5.2.1. Oral
- 5.2.2. Injectable
- 5.3. Market Analysis, Insights and Forecast - by End-user
- 5.3.1. Hospitals
- 5.3.2. Specialty Clinics
- 5.3.3. Other End-Users
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Middle East and Africa
- 5.4.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. North America Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Vaccine
- 6.1.1.1. JYNNEOS/Imvanex
- 6.1.1.2. Smallpox Vaccine
- 6.1.1.3. Other Products
- 6.1.2. Drugs
- 6.1.2.1. Tecovirimat
- 6.1.2.2. Brincidofovir
- 6.1.2.3. Other Drugs
- 6.1.3. Vaccinia Immune Globulin (VIG)
- 6.1.1. Vaccine
- 6.2. Market Analysis, Insights and Forecast - by Route of Administration
- 6.2.1. Oral
- 6.2.2. Injectable
- 6.3. Market Analysis, Insights and Forecast - by End-user
- 6.3.1. Hospitals
- 6.3.2. Specialty Clinics
- 6.3.3. Other End-Users
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. Europe Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Vaccine
- 7.1.1.1. JYNNEOS/Imvanex
- 7.1.1.2. Smallpox Vaccine
- 7.1.1.3. Other Products
- 7.1.2. Drugs
- 7.1.2.1. Tecovirimat
- 7.1.2.2. Brincidofovir
- 7.1.2.3. Other Drugs
- 7.1.3. Vaccinia Immune Globulin (VIG)
- 7.1.1. Vaccine
- 7.2. Market Analysis, Insights and Forecast - by Route of Administration
- 7.2.1. Oral
- 7.2.2. Injectable
- 7.3. Market Analysis, Insights and Forecast - by End-user
- 7.3.1. Hospitals
- 7.3.2. Specialty Clinics
- 7.3.3. Other End-Users
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. Asia Pacific Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Vaccine
- 8.1.1.1. JYNNEOS/Imvanex
- 8.1.1.2. Smallpox Vaccine
- 8.1.1.3. Other Products
- 8.1.2. Drugs
- 8.1.2.1. Tecovirimat
- 8.1.2.2. Brincidofovir
- 8.1.2.3. Other Drugs
- 8.1.3. Vaccinia Immune Globulin (VIG)
- 8.1.1. Vaccine
- 8.2. Market Analysis, Insights and Forecast - by Route of Administration
- 8.2.1. Oral
- 8.2.2. Injectable
- 8.3. Market Analysis, Insights and Forecast - by End-user
- 8.3.1. Hospitals
- 8.3.2. Specialty Clinics
- 8.3.3. Other End-Users
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Middle East and Africa Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Vaccine
- 9.1.1.1. JYNNEOS/Imvanex
- 9.1.1.2. Smallpox Vaccine
- 9.1.1.3. Other Products
- 9.1.2. Drugs
- 9.1.2.1. Tecovirimat
- 9.1.2.2. Brincidofovir
- 9.1.2.3. Other Drugs
- 9.1.3. Vaccinia Immune Globulin (VIG)
- 9.1.1. Vaccine
- 9.2. Market Analysis, Insights and Forecast - by Route of Administration
- 9.2.1. Oral
- 9.2.2. Injectable
- 9.3. Market Analysis, Insights and Forecast - by End-user
- 9.3.1. Hospitals
- 9.3.2. Specialty Clinics
- 9.3.3. Other End-Users
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. South America Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Vaccine
- 10.1.1.1. JYNNEOS/Imvanex
- 10.1.1.2. Smallpox Vaccine
- 10.1.1.3. Other Products
- 10.1.2. Drugs
- 10.1.2.1. Tecovirimat
- 10.1.2.2. Brincidofovir
- 10.1.2.3. Other Drugs
- 10.1.3. Vaccinia Immune Globulin (VIG)
- 10.1.1. Vaccine
- 10.2. Market Analysis, Insights and Forecast - by Route of Administration
- 10.2.1. Oral
- 10.2.2. Injectable
- 10.3. Market Analysis, Insights and Forecast - by End-user
- 10.3.1. Hospitals
- 10.3.2. Specialty Clinics
- 10.3.3. Other End-Users
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. North America Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Mexico
- 12. Europe Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 12.1.1 Germany
- 12.1.2 United Kingdom
- 12.1.3 France
- 12.1.4 Spain
- 12.1.5 Italy
- 12.1.6 Spain
- 12.1.7 Belgium
- 12.1.8 Netherland
- 12.1.9 Nordics
- 12.1.10 Rest of Europe
- 13. Asia Pacific Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 13.1.1 China
- 13.1.2 Japan
- 13.1.3 India
- 13.1.4 South Korea
- 13.1.5 Southeast Asia
- 13.1.6 Australia
- 13.1.7 Indonesia
- 13.1.8 Phillipes
- 13.1.9 Singapore
- 13.1.10 Thailandc
- 13.1.11 Rest of Asia Pacific
- 14. South America Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 14.1.1 Brazil
- 14.1.2 Argentina
- 14.1.3 Peru
- 14.1.4 Chile
- 14.1.5 Colombia
- 14.1.6 Ecuador
- 14.1.7 Venezuela
- 14.1.8 Rest of South America
- 15. North America Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 15.1.1 United States
- 15.1.2 Canada
- 15.1.3 Mexico
- 16. MEA Monkeypox Vaccine and Treatment Market Analysis, Insights and Forecast, 2019-2031
- 16.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 16.1.1 United Arab Emirates
- 16.1.2 Saudi Arabia
- 16.1.3 South Africa
- 16.1.4 Rest of Middle East and Africa
- 17. Competitive Analysis
- 17.1. Global Market Share Analysis 2024
- 17.2. Company Profiles
- 17.2.1 Chimerix Inc
- 17.2.1.1. Overview
- 17.2.1.2. Products
- 17.2.1.3. SWOT Analysis
- 17.2.1.4. Recent Developments
- 17.2.1.5. Financials (Based on Availability)
- 17.2.2 Tonix Pharmaceuticals Holding Corp *List Not Exhaustive
- 17.2.2.1. Overview
- 17.2.2.2. Products
- 17.2.2.3. SWOT Analysis
- 17.2.2.4. Recent Developments
- 17.2.2.5. Financials (Based on Availability)
- 17.2.3 Bavarian Nordic A/S
- 17.2.3.1. Overview
- 17.2.3.2. Products
- 17.2.3.3. SWOT Analysis
- 17.2.3.4. Recent Developments
- 17.2.3.5. Financials (Based on Availability)
- 17.2.4 SIGA Technologies
- 17.2.4.1. Overview
- 17.2.4.2. Products
- 17.2.4.3. SWOT Analysis
- 17.2.4.4. Recent Developments
- 17.2.4.5. Financials (Based on Availability)
- 17.2.1 Chimerix Inc
List of Figures
- Figure 1: Global Monkeypox Vaccine and Treatment Market Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: North America Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 3: North America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 4: Europe Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 5: Europe Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 6: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 7: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 8: South America Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 9: South America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: North America Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 11: North America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 12: MEA Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 13: MEA Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 14: North America Monkeypox Vaccine and Treatment Market Revenue (Million), by Product 2024 & 2032
- Figure 15: North America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Product 2024 & 2032
- Figure 16: North America Monkeypox Vaccine and Treatment Market Revenue (Million), by Route of Administration 2024 & 2032
- Figure 17: North America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 18: North America Monkeypox Vaccine and Treatment Market Revenue (Million), by End-user 2024 & 2032
- Figure 19: North America Monkeypox Vaccine and Treatment Market Revenue Share (%), by End-user 2024 & 2032
- Figure 20: North America Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 21: North America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 22: Europe Monkeypox Vaccine and Treatment Market Revenue (Million), by Product 2024 & 2032
- Figure 23: Europe Monkeypox Vaccine and Treatment Market Revenue Share (%), by Product 2024 & 2032
- Figure 24: Europe Monkeypox Vaccine and Treatment Market Revenue (Million), by Route of Administration 2024 & 2032
- Figure 25: Europe Monkeypox Vaccine and Treatment Market Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 26: Europe Monkeypox Vaccine and Treatment Market Revenue (Million), by End-user 2024 & 2032
- Figure 27: Europe Monkeypox Vaccine and Treatment Market Revenue Share (%), by End-user 2024 & 2032
- Figure 28: Europe Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 29: Europe Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 30: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue (Million), by Product 2024 & 2032
- Figure 31: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue Share (%), by Product 2024 & 2032
- Figure 32: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue (Million), by Route of Administration 2024 & 2032
- Figure 33: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 34: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue (Million), by End-user 2024 & 2032
- Figure 35: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue Share (%), by End-user 2024 & 2032
- Figure 36: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 37: Asia Pacific Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 38: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue (Million), by Product 2024 & 2032
- Figure 39: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue Share (%), by Product 2024 & 2032
- Figure 40: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue (Million), by Route of Administration 2024 & 2032
- Figure 41: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 42: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue (Million), by End-user 2024 & 2032
- Figure 43: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue Share (%), by End-user 2024 & 2032
- Figure 44: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 45: Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
- Figure 46: South America Monkeypox Vaccine and Treatment Market Revenue (Million), by Product 2024 & 2032
- Figure 47: South America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Product 2024 & 2032
- Figure 48: South America Monkeypox Vaccine and Treatment Market Revenue (Million), by Route of Administration 2024 & 2032
- Figure 49: South America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 50: South America Monkeypox Vaccine and Treatment Market Revenue (Million), by End-user 2024 & 2032
- Figure 51: South America Monkeypox Vaccine and Treatment Market Revenue Share (%), by End-user 2024 & 2032
- Figure 52: South America Monkeypox Vaccine and Treatment Market Revenue (Million), by Country 2024 & 2032
- Figure 53: South America Monkeypox Vaccine and Treatment Market Revenue Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Product 2019 & 2032
- Table 3: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 4: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by End-user 2019 & 2032
- Table 5: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Region 2019 & 2032
- Table 6: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 7: United States Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 8: Canada Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 9: Mexico Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 10: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 11: Germany Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: United Kingdom Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 13: France Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: Spain Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 15: Italy Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: Spain Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 17: Belgium Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 18: Netherland Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 19: Nordics Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 20: Rest of Europe Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 21: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 22: China Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 23: Japan Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 24: India Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 25: South Korea Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Southeast Asia Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 27: Australia Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Indonesia Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 29: Phillipes Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 30: Singapore Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 31: Thailandc Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 32: Rest of Asia Pacific Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 33: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 34: Brazil Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 35: Argentina Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 36: Peru Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 37: Chile Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 38: Colombia Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 39: Ecuador Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 40: Venezuela Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 41: Rest of South America Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 42: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 43: United States Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 44: Canada Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 45: Mexico Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 46: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 47: United Arab Emirates Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: Saudi Arabia Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 49: South Africa Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 50: Rest of Middle East and Africa Monkeypox Vaccine and Treatment Market Revenue (Million) Forecast, by Application 2019 & 2032
- Table 51: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Product 2019 & 2032
- Table 52: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 53: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by End-user 2019 & 2032
- Table 54: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 55: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Product 2019 & 2032
- Table 56: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 57: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by End-user 2019 & 2032
- Table 58: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 59: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Product 2019 & 2032
- Table 60: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 61: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by End-user 2019 & 2032
- Table 62: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 63: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Product 2019 & 2032
- Table 64: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 65: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by End-user 2019 & 2032
- Table 66: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
- Table 67: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Product 2019 & 2032
- Table 68: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 69: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by End-user 2019 & 2032
- Table 70: Global Monkeypox Vaccine and Treatment Market Revenue Million Forecast, by Country 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Monkeypox Vaccine and Treatment Market?
The projected CAGR is approximately 10.10%.
2. Which companies are prominent players in the Monkeypox Vaccine and Treatment Market?
Key companies in the market include Chimerix Inc, Tonix Pharmaceuticals Holding Corp *List Not Exhaustive, Bavarian Nordic A/S, SIGA Technologies.
3. What are the main segments of the Monkeypox Vaccine and Treatment Market?
The market segments include Product, Route of Administration, End-user.
4. Can you provide details about the market size?
The market size is estimated to be USD XX Million as of 2022.
5. What are some drivers contributing to market growth?
Increase in Prevalence of Monkeypox Infection; Government Initiatives to Combat Outbreak of Monkeypox.
6. What are the notable trends driving market growth?
JYNNEOS/Imvanex by Vaccine Segment is Expected to Witness Growth Over the Forecast Period.
7. Are there any restraints impacting market growth?
Side Effects Associated with the Vaccine and Treatment.
8. Can you provide examples of recent developments in the market?
September 2022: Bavarian Nordic A/S collaborated with the European Health Emergency Preparedness and Response Authority (HERA) for the supply of additional 170,000 doses of MVA-BN smallpox and monkeypox vaccine, which will be made available to EU Member States, Norway, and Iceland. Also, this new contract will give HERA twice as many monkeypox vaccines before the end of the year.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Monkeypox Vaccine and Treatment Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Monkeypox Vaccine and Treatment Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Monkeypox Vaccine and Treatment Market?
To stay informed about further developments, trends, and reports in the Monkeypox Vaccine and Treatment Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database



Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations

Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence